Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 5/20 | 0.49 |
| ▸ | NPY2R | P49146 | 2/20 | 0.46 |
| ▸ | NPY4R | P50391 | 2/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.46 |
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 4/20 | 0.44 |
| ▸ | F2 | P00734 | 4/20 | 0.42 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20866857 | 0.91 | NMUR2 (0.45) | NPY1RNPY2RNPY4RNPY5RNMUR2 | |
| SCHEMBL31556392 | 0.89 | NPY1R (0.50) | NPY1RNPY2RNPY4RNPY5RNMUR2 | |
| SCHEMBL20866859 | 0.88 | NMUR2 (0.45) | NPY1RNMUR2NMUR1NTSR2NTSR1 | |
| SCHEMBL11771442 | 0.87 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RNMUR2 | |
| SCHEMBL11771428 | 0.87 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RNMUR2 | |
| SCHEMBL20866863 | 0.87 | NTSR1 (0.56) | NPY1RNPY2RNPY4RNPY5RNTSR2 | |
| SCHEMBL20866854 | 0.86 | CAPN1 (0.42) | NPY1RNMUR2NMUR1XIAP | |
| SCHEMBL7309484 | 0.84 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RNMUR2 | |
| SCHEMBL7309499 | 0.84 | NPY1R (0.51) | NPY1RNPY2RNPY4RNPY5RNMUR2 | |
| SCHEMBL20866860 | 0.84 | NMUR2 (0.45) | NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255475-A1 | METABOLITE INSPIRED SELECTIVE OXYTOCIN RECEPTOR AGONISTS | Kinoxis Therapeutics Pty Ltd (AU) | 2020-08-13 | — | — | US | disclosed |
| WO-2019060962-A1 | METABOLITE INSPIRED SELECTIVE OXYTOCIN RECEPTOR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255475-A1 | METABOLITE INSPIRED SELECTIVE OXYTOCIN RECEPTOR AGONISTS | OXTR, AVPR2, AVPR1A | NPY1R 15/4885NPY2R 18/4885NPY4R 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.